Adjuvant therapies for special types of breast cancer

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Colleoni, Marco ^a   Russo, Leila ^b   Dellapasqua, Silvia ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer Adjuvant therapy Special types

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; UVOMORULIN;

ACCURACY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER RESEARCH; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG EFFICACY; DRUG TARGETING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; INTERNATIONAL COOPERATION; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STANDARDIZATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

EID: 79960997907     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70315-0     Document Type: Article

References (72)

1. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16:1569-1583.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
4. Ellis IO, Galea M, Broughton N, Locker A, Blarney RW, Elston CW Pathological prognostic factors in breast cancer. Histological type. Relationship with survival in a large study with long term follow-up. Histopathology 1992, 20:479-489.
5. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007, 18:1632-1640.
6. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004, 240:306-312.
7. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8:307-325.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sti USA 2001, 98:10869-10874.
9. Weigelt B, Baehner FL, Reis-Filho JS The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
10. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165.
11. Wirapati R, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancentoward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sti USA 2003, 100:8418-8423.
13. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006, 12:537-544.
14. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
16. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
17. Kim C, Paik S Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010, 7:340-347.
18. Page DL Special types of invasive breast cancer, with clinical implications. AmJ Surg Pathol 2003, 27:832-835.
19. Ellis P, Schnitt SJ, Sastre-Garau X Invasive breast carcinoma. Pathology and genetics of tumours of the breast and female genital organs: WHO classification of tumours series 2003, 13-48. IARC Press, Lyon, France. F.A. Tavassoli, P. Devilee (Eds.).
20. Yerushalmi R, Hayes MM, Gelmon KA Breast carcinoma-rare types: review of the literature. Ann Oncol 2009, 20:1763-1770.
21. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216:141-150.
22. Weigelt B, Geyer GC, Reis-Filho JS Histological types of breast cancer: How special are they?. Mol Oncol 2010, 4(3):192-208.
23. Weigelt B, Kreike B, Reis-Filho JS Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009, 117:273-280.
24. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007, 26:7859-7871.
25. Podo F, Buydens LMC, Degani H, Hilhorst R, Klipp E, Gribbestad IS, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010, 4:209-229.
26. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006, 66:4636-4644.
27. Moll R, Mitze M, Frixen UH, Birchmeier W Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993, 143:1731-1742.
28. Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe JC, et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008, 27:5359-5372.
29. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, et al. Germline E-Cadherin mutations in familial lobular breast cancer. J. Med Genet 2007, 44:726-731.
30. Reis-Filho JS, Simpson FT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006, 12:6652-6662.
31. Jayasinghe UW, Bilous AM, Boyages J Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?. BreastJ 2007, 13:479-485.
32. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO Morphologic and molecular evolutionary pathways of low nuclear grade invasive brest cancers and their putative precursor lesions further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008, 32:513-523.
33. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010, 220:45-57.
34. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JF, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. EurjSurg Oncol 1991, 17:251-257.
35. Toikkanen S, Pylkkanen L, Joensuu H Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997, 76:1234-1240.
36. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. Am Coll Surg 1998, 186:416-422.
37. Mersin H, Yildirim E, Gulben K, Berberoglu U Is invasive lobular carcinoma different from invasive ductal carcinoma?. EurJ Surg Oncol 2003, 29:390-395.
38. Arpino G, Bardou VJ, Clark GM, Elledge RM Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6:149-156.
39. Santiago RJ, Harris EE, Ojn L, Hwang WT, Solin LJ Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 2005, 103:2447-2454.
40. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, et al. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 2006, 7:396-400.
41. Jayasinghe UW, Bilous AM, Boyages J Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?. BreastJ 2007, 13:479-485.
42. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials.;. Clin Oncol 2008, 26:3006-3014.
43. Viale G, Rotmensz N, Maisonneuve P, Orvieto E, Maiorano E, Galimberti V, et al. Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 2009, 117:211-214.
44. Orvieto E, Maiorano E, Bottiglieri L Clinicopathologic characteristics of invasive lobular carcinoma of the breast. Results of an analysis of 530 cases from a single institution. Cancer 2008, 113:1511-1520.
45. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23:41-48.
46. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. EurJ Surg Oncol 2003, 29:361-367.
47. Chaturvedi S, Heys SD, Chaturvedi RS Primary chemotherapy for breast cancers: does histological type of cancer matter?. Breast Cancer Res Treat 2004, 88:S106. (abstr 2089).
48. Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 2005, 29:354-358.
49. Vincent-Salomon A, Pierga J-Y, Gautier C Neoadjuvant chemotherapy for invasive lobular carcinoma of the breast: a poorer response rate but not a worse prognosis than invasive ductal carcinoma. Breast Cancer Res Treat 2005, 94:S231. (abstr5071).
50. Baker RR Unusual lesions and their management. Surg Clin North Am 1990, 70:963-975.
51. Cooper HS, Patchefsky AS, Krall RA Tubular carcinoma of the breast. Cancer 1978, 42:2334-2342.
52. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010, 28:99-104.
53. Lopez-Garcia MA, Geyer FC, Natrajan R, Kreike B, Mackay A, Grigoriadis A, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol 2010, 222:64-75.
54. Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ Invasive cribriform carcinoma of the breast. Histopathology 1983, 7:525-536.
55. Clayton F Pure mucinous carcinomas of breast: morphologic features and prognostic correlates. Hum Pathol 1986, 17:34-38.
56. Rosen PP, Groshen S, Kinne DW, Norton L Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993, 11:2090-2100.
57. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
58. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977, 40:1365-1385.
59. Rapin V, Contesso G, Mouriesse HE, Bertin F, Lacombe MJ, Piekarski JD, et al. Medullary breast carcinoma: a reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988, 61:2503-2510.
60. Trendell-Smith NJ, Peston D, Shousha S Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins. Histopathology 1999, 35:241-248.
61. Costa NM, Rodrigues H, Pereira H, Pardal F, Matos E Secretory breast carcinoma-case report and review of the medical literature. Breast 2004, 13:353-355.
62. Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer 1999, 85:2170-2182.
63. Kaufman MW, Marti JR, Gallager HS, Hoehn JL Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer 1984, 53:1908-1917.
64. Rakha EA, Lee AHS, Evans AJ, Menon S, Assad NY, Hodi Z, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010, 28:99-104.
65. Tresserra F, Grases PJ, Fabregas R, Fernandez-Cid A, Dexeus S Invasive micropapillary carcinoma: distinct features of a poorly recognized variant of breast carcinoma. EurJ Gynaecol Oncol 1999, 20:205-208.
66. Paterakos M, Watkin WG, Edgerton SM, Moore DH, Thor AD Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol 1999, 30:1459-1463.
67. Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, et al. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity?. Breast 2005, 14:3-10.
68. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
69. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010, 23:644-653.
70. Murakami A, Kawachi K, Sasaki T, Ishikawa T, Nagashima Y, Nozawa A Sebaceous carcinoma of the breast. Pathol Int 2009, 59:188-192.
71. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer. J din. Oncol 2006, 24:3726-3734.
72. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.